Emergent BioSolutions | EBS


Peers Price Chg Day Year Date
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
ALKERMES 29.94 1.02 3.53% 11.47% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Amarin 15.33 0.30 2.00% 27.64% Sep/05
ANI Pharmaceuticals 95.35 -0.65 -0.68% 57.58% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Exact Sciences 53.81 2.40 4.67% -8.97% Sep/05
Exelixis 37.88 0.50 1.34% 50.62% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Ironwood Pharmaceuticals 1.16 0.06 5.45% -74.28% Sep/05
Lonza 577.40 -0.80 -0.14% 7.68% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Myriad Genetics 6.61 -0.18 -2.65% -75.49% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
United Therapeutics 400.52 20.05 5.27% 15.88% Sep/05

Indexes Price Day Year Date
US2000 2391 11.44 0.48% 14.33% Sep/05
US400 3297 16.31 0.50% 12.16% Sep/05

Emergent BioSolutions traded at $2.31 this Tuesday April 9th, decreasing $0.01 or 0.43 percent since the previous trading session. Looking back, over the last four weeks, Emergent BioSolutions lost 17.50 percent. Over the last 12 months, its price fell by 81.34 percent. Looking ahead, we forecast Emergent BioSolutions to be priced at 2.29 by the end of this quarter and at 2.23 in one year, according to Trading Economics global macro models projections and analysts expectations.

Emergent BioSolutions Inc. is a life sciences company focused on providing civilian and military populations with a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). The Company is focused on five PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). It operates through four business units, which includes three product business units: Vaccines, Devices, Therapeutics; and one services business unit: CDMO. The Company's contract development and manufacturing service offerings cover development services, drug substance manufacturing and drug product manufacturing across the pharmaceutical and biotechnology industries as well as the United States Government (USG) and non-Governmental organizations.